Loading...
Keywords
Last Name
Institution

Connection

Search Results to Alan S. Gamis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Gamis, Alan

PropertyValue
keywords Pediatric Hematology/Oncology
research overview Dr. Gamis' research expertise is in the design and development of multi-institutional clinical trials in childhood cancer, specifically in AML. He is a board certified Pediatric Hematologist/Oncologist and continue to care for patients with cancer in a large children's cancer center. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. He has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the phase III trial COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the present. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time we designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original PI of a clinical core center of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008. Locally, as the Director of the Children's Mercy Cancer Center, Dr. Gamis oversee all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center.

One or more keywords matched the following items that are connected to Gamis, Alan

Item TypeName
Concept Hospitals, Pediatric
Concept Pediatrics
Concept Intensive Care Units, Pediatric
Concept Drug Discovery
Academic Article Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer.
Academic Article Nitrous oxide analgesia in a pediatric emergency department.
Academic Article Acute acetone intoxication in a pediatric patient.
Academic Article Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
Academic Article Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Academic Article Surveys: a tool to provoke thought and identify areas of need.
Academic Article Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group.
Academic Article Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma.
Academic Article High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.
Academic Article Differentiating between congenital rhabdomyosarcoma versus fibromatosis of the pediatric tongue.
Academic Article Prognostic factors in pediatric acute myeloid leukemia.
Academic Article WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
Academic Article Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Academic Article Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
Academic Article FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
Academic Article Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.
Academic Article High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.
Academic Article Relationship between pediatric blood and marrow transplant center volume and day +100 mortality: Pediatric Blood and Marrow Transplant Consortium experience.
Academic Article Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
Academic Article Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
Academic Article Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
Academic Article The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
Academic Article Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
Academic Article BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group.
Academic Article High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Academic Article Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
Academic Article Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Academic Article Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group.
Academic Article A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
Academic Article Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.
Academic Article A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.
Academic Article CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Academic Article Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
Academic Article Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report.
Academic Article miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Academic Article Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group.
Academic Article Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Academic Article Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Academic Article Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
Academic Article Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Academic Article Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Academic Article MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Academic Article The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
Academic Article Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
Academic Article Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.
Academic Article Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
Academic Article Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
Academic Article Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Academic Article Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.
Academic Article Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
Academic Article Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Academic Article Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Academic Article Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Academic Article Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA.
Academic Article Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Academic Article Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Academic Article Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
Academic Article Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.

Search Criteria
  • Drug Discovery
  • Pediatric
  • Oncology